Physician profile
Satish Patel
NPI 1790746774
$8,876.56
in general payments reported to CMS, 2019-2025
47 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,804 · 2020: $871 · 2021: $695 · 2022: $1,340 · 2023: $1,676 · 2024: $1,168 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,165 · Education: $2.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,165.02 |
| Education | $2.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,613.64 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $1,371.50 | 2021-2025 | |
| Amgen INC. | $718.36 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $561.32 | 2019-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $529.53 | 2019-2025 | Rexulti |
| Allergan, INC. | $510.23 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $497.73 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $385.17 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.36 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $337.39 | 2020-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $250.89 | 2019-2023 | |
| Sk Life Science, INC. | $163.39 | 2023 | Xcopri |
| Janssen Pharmaceuticals, INC | $153.46 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.44 | 2023-2025 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $98.48 | 2019-2021 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $97.69 | 2024 | Voquezna |
| Abbott Laboratories | $84.76 | 2019-2025 | Freestyle Libre 3 |
| Hikma Pharmaceuticals USA | $71.64 | 2019-2023 | Ryaltris, Mitigare |
| Kerecis Limited | $66.48 | 2021 | |
| Axsome Therapeutics, INC. | $64.15 | 2023-2024 | Auvelity |
| Ardelyx, INC. | $60.39 | 2025 | Ibsrela |
| Mylan Specialty L.P. | $58.93 | 2020-2023 | Yupelri |
| Ironwood Pharmaceuticals, INC | $58.63 | 2019-2021 | |
| Vivus LLC | $54.79 | 2019 | |
| Lundbeck LLC | $47.73 | 2020-2024 | Rexulti |
| Ethicon US, LLC | $45.68 | 2019 | |
| Insulet Corporation | $42.90 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $38.35 | 2022-2023 | Gvoke Hypopen |
| Evoke Pharma, INC. | $38.09 | 2021-2022 | |
| Eisai INC. | $37.63 | 2020 | |
| Dexcom, INC. | $37.16 | 2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $34.78 | 2023-2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $32.64 | 2022-2023 | |
| Madrigal Pharmaceuticals | $28.60 | 2025 | Rezdiffra |
| Medtronic USA, INC. | $21.56 | 2019 | |
| Tactile Systems Technology INC | $20.33 | 2025 | Flexitouch Plus, Nimbl |
| Harmony Biosciences LLC | $18.78 | 2024 | |
| Shire North American Group INC | $18.56 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.57 | 2022 | |
| Glaxosmithkline, LLC. | $15.53 | 2025 | Trelegy Ellipta |
| Genentech USA, INC. | $14.99 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.96 | 2021 | |
| Vifor Pharma, INC. | $14.93 | 2019 | |
| Circassia INC. | $14.82 | 2019 | |
| Esperion Therapeutics, INC. | $14.62 | 2020 | |
| Astellas Pharma US INC | $11.27 | 2019 | |
| Romark Laboratories, Lc | $9.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.